 |
|
|
| |
High Dose Pegasys/rbv can improve SVR: Impact of higher doses of peginterferon alfa-2a and ribavirin on RVR, cEVR and SVR in HCV G1 patients with viral loads ≥400 000 IU/mL weighing ≥85 kg
|
| |
| |
Reported by Jules Levin
EASL Apr 14-18 2010 Vienna Austria
K.R. Reddy,1 M.L. Shiffman,2 M. Rodriguez-Torres,3 D. Abdurakhmanov,4 I. Bakulin,5 G.F. Silva,6 H. Cheinquer,7 M. Rabbia,8 M. McKenna,9 A. Tietz,10 S.A. Harrison,11 on behalf of the PROGRESS Study Investigators
1Hospital of the University of Pennsylvania, Philadelphia, PA, USA; 2Liver Institute of Virginia, Bon Secours Health System, Newport News, VA, USA; 3Fundacion de Investigacion de Diego, Santurce, PR, USA; 4Moscow Medical Academy, Moscow, Russia; 5State Postgraduate Medical Institute,
Ministry of Defence of the Russian Federation, Moscow, Russia; 6Botucatu School of Medicine, Botucatu, Brazil; 7Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil; 8Roche, Nutley, NJ, USA; 9Roche, Welwyn, UK; 10Roche, Basel, Switzerland; 11Brooke Army Medical Center, Houston, TX, USA
This research was funded by Roche, Basel, Switzerland
Figure 1. PROGRESS study design
Figure 2. Virological response rates for the four treatment arms
Figure 3. SVR rates in patients receiving ≥80% of the cumulative dose of peginterferon alfa-2a and ribavirin
Figure 4. Predictors of SVR
Figure 5. SVR rates according to on-treatment responses
Figure 6. SVR rates according to (A) baseline NAS, (B) baseline steatosis score, (C) baseline homeostasis model of assessment-insulin resistance (HOMA-IR) and (D) baseline body weight
|
| |
|
|
|
|
|
